Video

Dr. Pecora on his Personal Involvement in Research

Author(s):

Andrew L. Pecora, MD, FACP, CPE

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Andrew L. Pecora, M.D., F.A.C.P., C.P.E. Chief Innovations Officer, Professor and Vice President of Cancer Services at John Theurer Cancer Center, on his personal involvement in research.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Related Content
FDA
November 19th 2024

FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML